LabTech(SH:688056) EBSCN·2025-08-29 04:06Investment Rating - The report maintains an "Accumulate" rating for the company [5] Core Views - The company reported a revenue of 192 million yuan for the first half of 2025, a year-on-year decrease of 10.33%, with a net profit attributable to shareholders of 21 million yuan, down 11.53% year-on-year [1] - The overall gross margin slightly increased to 45.55%, up 0.86 percentage points year-on-year, driven by improved margins in the experimental analysis instruments segment [1] - The company is focusing on high-end product lines, with R&D expenses accounting for 12.30% of revenue, an increase of 0.64 percentage points year-on-year [2] - The company aims to enhance its core competitiveness in high-end analytical instruments, particularly in mass spectrometry technology [2] - Short-term performance is under pressure due to weak market demand, leading to a downward revision of net profit forecasts for 2025 and 2026 [3] Summary by Sections Financial Performance - In H1 2025, revenue from experimental analysis instruments was 151 million yuan, down 2.02% year-on-year, while revenue from clean environmental laboratory solutions decreased by 57.02% [1] - The company controlled its selling, general, and administrative expenses, which decreased by approximately 5% year-on-year [1] R&D and Innovation - R&D investment in H1 2025 was 23.62 million yuan, a decrease of 5.38% year-on-year, but the number of authorized patents increased significantly [2] - The company is advancing projects in high-end analytical instruments, including ICP-MS, to support domestic substitution and national productivity [2] Profit Forecast and Valuation - The revised net profit forecasts for 2025 and 2026 are 50 million yuan and 58 million yuan, respectively, with an expected EPS of 0.74 yuan for 2025 [3][4] - The current stock price corresponds to a P/E ratio of 54 for 2025, 46 for 2026, and 40 for 2027 [3][4]